

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

215309Orig1s000

OFFICER/EMPLOYEE LIST

MEMORANDUM

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

DATE: 22 September 2021

TO: Administrative file for NDA 215309

FROM: Matthew White, Regulatory Health Project Manager
Division of Dermatology and Dentistry, Office of Immunology and Inflammation

SUBJECT: Officer/Employee List for NDA 215309

APPLICATION/DRUG: NDA 215309, OPZELURA (ruxolitinib) cream

The following officers or employees of FDA participated in the decision to approve this application and consented to be identified on this list:

Ayalew, Kassa	Shafiei, Hamid
Bauerlien, Melinda	Strasinger, Caroline
Bui-Nguyen, Tri	Thomas, Dustin
Buonaccorsi, Laurie	Wackes, Frank
Choudhry, Yasmin	Wang, Jianyong
Daniels, Selena	Weissfeld, Joel
Dinatale, Miriam	Wells, Jesse
Doddapaneni, Suresh	Wilson, Wendy
Fritsch, Kathleen	Zhang, Da
Griffiths, LaShawn	
Hill, Barbara A	
Hutchins, Shawna	
Kolejian, Sevan	
Limpert, Jeannie	
Liu, Jiang	
Marcus, Kendall	
Nguyen, Phuc	
Oussova, Tatiana	
Papadopoulos, Elektra	
Redwood, Susan	
Sandhu, Sukhminder	